We are building a leading, next generation precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology

The Key differentiation of ACT® is:

ACT® has a biomechanical mode of action to increase the uptake of co-administered drugs from blood vessels into the surrounding (cancer) tissue, without damaging the cells within the capillary walls; unlike sonoporation, ACT® does not create holes in the epithelial cell membranes of the capillary wall.

With ACT®, the drug can reach IOO microns which is 10 layers of cells away from capillary with an ongoing pump effect that lasts for minutes.

Reproducible and signifcant uptake through targeted delivery into tumours and across the blood brain barrier (BBB).

A very strong toxicology package: including most recently, in relation to BBB opening where no extravasation of red blood cells was observed throughout the ACT® procedure in a preclinical rodent model.

Uses a bespoke dual frequency transducer with a standard ultrasound scanner to activate and enhance the clusters at the target tumour site. Compatible with existing ultrasound systems widely available in clinics/hospitals worldwide.

No drug reformulation required.

ACT® relies on ultrasound settings well within safe and approved ranges.

State of the art navigation system in development to ensure ACT® is delivered accurately at a targeted site